Last reviewed · How we verify

OraVescent fentanyl (OVF)

Cephalon · Phase 3 active Small molecule

OraVescent fentanyl is a rapid-onset opioid agonist delivered via an effervescent oral formulation that enhances buccal absorption of fentanyl for fast pain relief.

OraVescent fentanyl is a rapid-onset opioid agonist delivered via an effervescent oral formulation that enhances buccal absorption of fentanyl for fast pain relief. Used for Breakthrough pain in opioid-tolerant cancer patients.

At a glance

Generic nameOraVescent fentanyl (OVF)
SponsorCephalon
Drug classOpioid agonist
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

OraVescent fentanyl uses an effervescent tablet technology that creates CO₂ bubbles in the mouth, increasing surface area contact with buccal mucosa and accelerating fentanyl absorption compared to standard oral formulations. This mechanism allows fentanyl—a mu-opioid receptor agonist—to reach therapeutic levels more rapidly, making it suitable for breakthrough pain management. The formulation bypasses first-pass hepatic metabolism by utilizing transmucosal absorption.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: